TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06550141: Emapalumab Prevention of CAR-T Cell Associated Toxicities

Sponsor: Marcela V. Maus, M.D.,Ph.D. · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 28 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$11,134,200

Rescue Site Savings

+$7,345,800

Unlock Full NCT06550141 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06550141 Rescue Dossier →